Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
HeraMED Ltd. ( (AU:HMD) ) has shared an update.
HeraMED Ltd. has disclosed a change in director Timothy Chapman’s indirect interest in the company, lodged under ASX listing rule requirements. The notice details his holdings via Inverness Capital Pty Ltd, where he is a director, shareholder of the trustee, and a beneficiary of the trust.
Chapman has been issued 2,500,000 performance rights at nil consideration, following shareholder approval at an extraordinary general meeting on 26 March 2026. The performance rights vest subject to a 20-day VWAP hurdle of $0.0528 by 14 January 2027 and must be exercised within 18 months of vesting, aligning his incentives with future share price performance and long-term value creation for investors.
More about HeraMED Ltd.
HeraMED Ltd. is an Australian-listed company, with its shares traded on the ASX. The company operates in the healthcare technology sector, focusing on connected medical solutions, although this filing centers on corporate governance and director interests rather than products or services.
YTD Price Performance: 36.11%
Average Trading Volume: 1,595,153
Technical Sentiment Signal: Buy
Current Market Cap: A$56.59M
For an in-depth examination of HMD stock, go to TipRanks’ Overview page.